Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-05-2020 | Oculoplastics and Orbit

4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves’ orbitopathy

Authors: Yeonjung Yoon, Min Kyung Chae, Eun Jig Lee, Jin Sook Yoon

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 5/2020

Abstract

Purpose

In Graves’ orbitopathy (GO), hyaluronan secreted by orbital fibroblasts contributes to orbital tissue expansion. The goal of this research was to evaluate the potential benefit of 4-methylumbelliferone (4-MU), a hyaluronan synthase (HAS) inhibitor, in primary cultured orbital fibroblasts from Graves’ orbitopathy.

Methods

We assessed the viability of orbital fibroblasts using a live/dead cell assay. Hyaluronan synthesis was evaluated by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR (qPCR). Adipogenesis was assessed by Oil Red O staining and qPCR of adipogenic transcription factors.

Results

In orbital fibroblasts treated with 4-MU (up to 1000 μM), cell viability was preserved by 90%. 4-MU significantly inhibited HAS gene expression and hyaluronan production (*P < 0.05). With respect to adipogenesis, 4-MU suppressed the accumulation of lipids and reduced the number of adipocytes, while decreasing expression of adipogenic transcription factors.

Conclusions

4-MU represents a promising new therapeutic agent for GO based on its ability to inhibit hyaluronan production and adipogenesis, without decreasing cell viability.

Available only for authorised users

Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362:726–738. https://doi.org/10.1056/NEJMra0905750 CrossRefPubMedPubMedCentral

Huang Y, Fang S, Li D, Zhou H, Li B, Fan X (2019) The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye(Lond) 33:177–182. https://doi.org/10.1038/s41433-018-0279-9 CrossRef

Smith TJ (2019) Potential roles of CD34+ fibrocytes masquerading as orbital fibroblasts in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 104:581–594. https://doi.org/10.1210/jc.2018-01493 CrossRefPubMed

Jiang D, Liang J, Noble PW (2011) Hyaluronan as an immune regulator in human diseases. Physiol Rev 91:221–264. https://doi.org/10.1152/physrev.00052.2009 CrossRefPubMed

Medina CO, Nagy N, Bollyky PL (2018) Extracellular matrix and the maintenance and loss of peripheral immune tolerance in autoimmune insulitis. Curr Opin Immunol 55:22–30. https://doi.org/10.1016/j.coi.2018.09.006 CrossRefPubMedPubMedCentral

Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC (2015) Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J Clin Endocrinol Metab 100:1071–1077. https://doi.org/10.1210/jc.2014-3566 CrossRefPubMed

Kuipers HF, Nagy N, Ruppert SM, Sunkari VG, Marshall PL, Gebe JA, Ishak HD, Keswani SG, Bollyky J, Frymoyer AR, Wight TN, Steinman L, Bollyky PL (2016) The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice. Clin Exp Immunol 185:372–381. https://doi.org/10.1111/cei.12815 CrossRefPubMedPubMedCentral

Yoshida E, Kudo D, Nagase H, Shimoda H, Suto S, Negishi M, Kakizaki I, Endo M, Hakamada K (2016) Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer. Oncol Lett 12:2337–2344. https://doi.org/10.3892/ol.2016.4930 CrossRefPubMedPubMedCentral

Wang R, Zhou W, Wang J, Liu Y, Chen Y, Jiang S, Luo X, Stupack DG, Luo N (2015) Role of hyaluronan and glucose on 4-methylumbelliferone-inhibited cell proliferation in breast carcinoma cells. Anticancer Res 35:4799–4805PubMed

10.

Piccioni F, Fiore E, Bayo J, Atorrasagasti C, Peixoto E, Rizzo M, Malvicini M, Tirado-Gonzalez I, Garcia MG, Alaniz L, Mazzolini G (2015) 4-Methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis. Glycobiology 25:825–835. https://doi.org/10.1093/glycob/cwv023 CrossRefPubMed

11.

Abate A, Dimartino V, Spina P, Costa PL, Lombardo C, Santini A, Del Piano M, Alimonti P (2001) Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, double-blind, placebo-controlled clinical study. Drugs Exp Clin Res 27:223–231PubMed

12.

Kim SE, Lee JH, Chae MK, Lee EJ, Yoon JS (2016) The role of Sphingosine-1-phosphate in adipogenesis of Graves’ orbitopathy. Invest Ophthalmol Vis Sci 57:301–311. https://doi.org/10.1167/iovs.15-17863 CrossRefPubMed

13.

Hamada S, Nishida Y, Zhuo L, Shinomura T, Ikuta K, Arai E, Koike H, Kimata K, Ushida T, Ishiguro N (2018) Suppression of hyaluronan synthesis attenuates the tumorigenicity of low-grade chondrosarcoma. J Orthop Res 36:1573–1580. https://doi.org/10.1002/jor.23794 CrossRefPubMed

14.

Kultti A, Pasonen-Seppanen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E, Tammi RH, Tammi MI (2009) 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 315:1914–1923. https://doi.org/10.1016/j.yexcr.2009.03.002 CrossRefPubMed

15.

Ban H, Uchakina O, McKallip RJ (2015) Hyaluronic acid inhibitor 4-methylumbelliferone activates the intrinsic apoptosis pathway in K562 chronic myelogenous leukemia cells. Anticancer Res 35(10):5231–5240PubMed

16.

Karousou E, Misra S, Ghatak S, Dobra K, Gotte M, Vigetti D, Passi A, Karamanos NK, Skandalis SS (2017) Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol 59:3–22. https://doi.org/10.1016/j.matbio.2016.10.001 CrossRefPubMed

17.

Yoshida E, Kudo D, Nagase H, Suto A, Shimoda H, Suto S, Kakizaki I, Endo M, Hakamada K (2018) 4-Methylumbelliferone decreases the Hyaluronan-rich extracellular matrix and increases the effectiveness of 5-fluorouracil. Anticancer Res 38:5799–5804. https://doi.org/10.21873/anticanres.12919 CrossRefPubMed

18.

McKallip RJ, Ban H, Uchakina ON (2015) Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses LPS-induced lung inflammation. Inflammation 38:1250–1259. https://doi.org/10.1007/s10753-014-0092-y CrossRefPubMed

19.

Collum SD, Chen NY, Hernandez AM, Hanmandlu A, Sweeney H, Mertens TCJ, Weng T, Luo F, Molina JG, Davies J, Horan IP, Morrell NW, Amione-Guerra J, Al-Jabbari O, Youker K, Sun W, Rajadas J, Bollyky PL, Akkanti BH, Jyothula S, Sinha N, Guha A, Karmouty-Quintana H (2017) Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis. Br J Pharmacol 174:3284–3301. https://doi.org/10.1111/bph.13947 CrossRefPubMedPubMedCentral

20.

Bollyky PL, Evanko SP, Wu RP, Potter-Perigo S, Long SA, Kinsella B, Reijonen H, Guebtner K, Teng B, Chan CK, Braun KR, Gebe JA, Nepom GT, Wight TN (2010) Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse. Cell Mol Immunol 7:211–220. https://doi.org/10.1038/cmi.2010.9 CrossRefPubMedPubMedCentral

21.

Mueller AM, Yoon BH, Sadiq SA (2014) Inhibition of hyaluronan synthesis protects against central nervous system (CNS) autoimmunity and increases CXCL12 expression in the inflamed CNS. J Biol Chem 289:22888–22899. https://doi.org/10.1074/jbc.M114.559583 CrossRefPubMedPubMedCentral

22.

Ji E, Jung MY, Park JH, Kim S, Seo CR, Park KW, Lee EK, Yeom CH, Lee S (2014) Inhibition of adipogenesis in 3T3-L1 cells and suppression of abdominal fat accumulation in high-fat diet-feeding C57BL/6J mice after downregulation of hyaluronic acid. Int J Obes 38:1035–1043. https://doi.org/10.1038/ijo.2013.202 CrossRef

23.

Tasdemir E, Atmaca M, Yildirim Y, Bilgin HM, Demirtas B, Obay BD, Kelle M, Oflazoglu HD (2017) Influence of coumarin and some coumarin derivatives on serum lipid profiles in carbontetrachloride-exposed rats. Hum Exp Toxicol 36:295–301. https://doi.org/10.1177/0960327116649675 CrossRefPubMed

24.

Nagy N, Kuiper HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, Bollyky PL (2015) 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol 6:123. https://doi.org/10.3389/fimmu.2015.00123 CrossRefPubMedPubMedCentral

25.

Hoffmann RM, Schwarz G, Pohl C, Ziegenhagen DJ, Kruis W (2005) Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility. Dtsch Med Wochenschr 130:1938–1943CrossRefPubMed

26.

Garrett ER, Venitz J (1994) Comparisons of detections, stabilities, and kinetics of degradation of hymecromone and its glucuronide and sulfate metabolites. J Pharm Sci 83:115–116. https://doi.org/10.1002/jps.2600830128 CrossRefPubMed

27.

McKallip RJ, Hagele HF, Uchakina ON (2013) Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation. Toxins (Basel) 5:1814–1826. https://doi.org/10.3390/toxins5101814 CrossRef

28.

Yoshioka Y, Kozawa E, Urakawa H, Arai E, Futamura N, Zhuo L, Kimata K, Ishiguro N, Nishida Y (2013) Suppression of hyaluronan synthesis alleviates inflammatory responses in murine arthritis and in human rheumatoid synovial fibroblasts. Arthritis Rheum 65:1160–1170. https://doi.org/10.1002/art.37861 CrossRefPubMed

29.

Trabucchi E, Baratti C, Centemero A, Zuin M, Rizzitelli E, Colombo R (1986) Controlled study of the effects of tiropramide on biliary dyskinesia. Pharmatherapeutica 4:541–550PubMed

30.

Banga JP, Moshkelgosha S, Berchner-Pfannschmidt U, Eckstein A (2015) Modeling Graves’ orbitopathy in experimental Graves’ disease. Horm Metab Res 47:797–803. https://doi.org/10.1055/s-0035-1555956 CrossRefPubMed

31.

Floegel U, Schlueter A, Jacoby C, Temme S, Banga JP, Eckstein A, Schrader J, Berchner-Pfannschmidt U (2018) Multimodal assessment of orbital immune cell infiltration and tissue remodeling during development of Graves disease by 1H19F MRI. Magn Reson Med 80:711–718. https://doi.org/10.1002/mrm.27064 CrossRef

32.

Shen WC, Lee CH, Loh EW, Hsieh AT, Chen L, Tam KW (2018) Efficacy and safety of rituximab for the treatment of Graves’ orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy 38:503–510. https://doi.org/10.1002/phar.2111 CrossRefPubMed

33.

Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748–1761. https://doi.org/10.1056/NEJMoa1614949 CrossRefPubMedPubMedCentral

Title: 4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves’ orbitopathy
Authors: Yeonjung Yoon
Min Kyung Chae
Eun Jig Lee
Jin Sook Yoon
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 5/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-019-04528-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves’ orbitopathy

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2020

Alteration of choroidal vascular structure in diabetic macular edema

Micropulse transscleral cyclophotocoagulation: initial results using a reduced energy protocol in refractory glaucoma

Reply to “Does hand hygiene reduce SARS-CoV-2 transmission?”

Investigation of the therapeutic mechanism of subthreshold micropulse laser irradiation in retina

Assessment of corneal topographic, tomographic, densitometric, and biomechanical properties of Fabry patients with ocular manifestations

Corticosteroid eyedrops induced blepharoptosis and atrophy of levator muscle